Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Madrigal Pharmaceuticals Inc (MDGL)  
$205.25 1.67 (0.81%) as of 4:30 Fri 5/10


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 19,740,000
Market Cap: 4.05(B)
Last Volume: 9,322,967 Avg Vol: 9,297,189
52 Week Range: $120.4 - $292.92
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Diagnostic Substances

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    : 27
Insider 3/6 Months : 27.6
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Co.'s primary product candidate, resmetirom, is being developed as a once-daily oral pill to treat several disease states, including non-alcoholic steatohepatitis, or NASH. Co. has initiated MAESTRO-NASH, a Phase 3 trial in NASH with its once daily, oral thyroid hormone receptor beta selective agonist, resmetirom. Co. has opened for enrollment MAESTRO-NAFLD-1, a Phase 3 clinical study of patients with biopsy-confirmed or presumed NASH recruited from sites in the U.S.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 424,685 424,685 424,685
Total Buy Value $0 $77,751,391 $77,751,391 $77,751,391
Total People Bought 0 1 1 1
Total Buy Transactions 0 10 10 10
Total Shares Sold 252,542 270,142 270,142 339,631
Total Sell Value $62,399,106 $66,219,580 $66,219,580 $85,688,008
Total People Sold 5 7 7 8
Total Sell Transactions 13 21 21 26
End Date 2024-02-11 2023-11-10 2023-05-12 2022-05-12

   
Records found: 413
  Page 3 of 17  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Lynch Brian Joseph SVP and General Counsel   •       –      –    2023-12-05 4 OE $87.09 $87,090 D/D 1,000 16,001     -
   Lynch Brian Joseph SVP and General Counsel   •       –      –    2023-12-04 4 S $215.73 $393,964 D/D (1,800) 15,001 -4%     
   Lynch Brian Joseph SVP and General Counsel   •       –      –    2023-12-04 4 OE $73.75 $146,090 D/D 1,800 16,801     -
   Lynch Brian Joseph SVP and General Counsel   •       –      –    2023-11-30 4 S $203.00 $613,730 D/D (3,000) 15,001 -21%     
   Lynch Brian Joseph SVP and General Counsel   •       –      –    2023-11-30 4 OE $73.75 $221,250 D/D 3,000 18,001     -
   Lynch Brian Joseph SVP and General Counsel   •       –      –    2023-11-29 4 S $198.40 $796,750 D/D (4,000) 15,001 -24%     
   Lynch Brian Joseph SVP and General Counsel   •       –      –    2023-11-29 4 OE $73.75 $295,000 D/D 4,000 19,001     -
   Baker Brothers Life Sciences Lp Director   –       •      –    2023-11-21 4 B $183.16 $12,128,340 I/I 64,350 1,667,104 2.1 30%     
   Huntsman Carole Chief Commercial Officer   •       –      –    2023-11-20 4 A $0.00 $0 D/D 7,834 7,834     -
   Baker Brothers Life Sciences Lp Director   –       •      –    2023-11-20 4 B $181.93 $3,846,575 I/I 20,709 1,607,668 2.1 29%     
   Baker Brothers Life Sciences Lp Director   –       •      –    2023-11-17 4 B $167.63 $8,100,704 I/I 46,370 1,588,541 2.1 45%     
   Baker Brothers Life Sciences Lp Director   –       •      –    2023-11-15 4 B $161.97 $2,461,721 I/I 15,199 1,545,775 2.1 60%     
   Baker Brothers Life Sciences Lp Director   –       •      –    2023-11-14 4 B $152.21 $5,799,653 I/I 37,660 1,500,227 2.1 58%     
   Baker Brothers Life Sciences Lp Director   –       •      –    2023-11-14 4 B $156.42 $5,347,837 I/I 34,188 1,531,757 2.1 58%     
   Baker Brothers Life Sciences Lp Director   –       •      –    2023-11-13 4 B $136.18 $10,001,368 I/I 69,839 1,465,494 2.1 70%     
   Sibold William John President and CEO   •       •      –    2023-09-11 4 A $0.00 $0 D/D 50,000 50,000     -
   Waltermire Robert E. Senior VP, Chief Pharma Dev.   •       –      –    2023-03-01 4 S $273.44 $1,372,081 D/D (5,000) 5,667 21%     
   Waltermire Robert E. Senior VP, Chief Pharma Dev.   •       –      –    2023-03-01 4 OE $87.92 $439,600 D/D 5,000 10,667     -
   Waltermire Robert E. Senior VP, Chief Pharma Dev.   •       –      –    2023-02-28 4 S $271.03 $1,360,357 D/D (5,000) 5,667 19%     
   Waltermire Robert E. Senior VP, Chief Pharma Dev.   •       –      –    2023-02-28 4 OE $87.92 $439,600 D/D 5,000 10,667     -
   Craves Fred B Director   –       •      –    2023-01-30 4 GD $0.00 $0 I/I 3,557 57,062     -
   Levy Richard S Director   –       •      –    2023-01-17 4 AS $285.28 $6,592,686 D/D (22,489) 9,100 -5%     
   Levy Richard S Director   –       •      –    2023-01-17 4 OE $100.45 $2,316,844 D/D 22,489 31,589     -
   Friedman Paul A   –       •      –    2023-01-16 4 D $243.92 $549,796 D/D (2,254) 20,001     -
   Howarth Alex G. Chief Financial Officer   •       –      –    2023-01-16 4 A $0.00 $0 D/D 15,001 15,001     -
  413 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 3 of 17
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us